background-image
Abbreviations:

4-1BB, tumor necrosis factor receptor superfamily member 9; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; APRIL, a proliferation inducing ligand; BAFF, B-cell activating factor from the tumor necrosis factor family; BAK, Bcl-2 homologous antagonist killer; BAX, Bcl-2-associated X protein; BCL-2, B-cell lymphoma 2; BCMA, B-cell maturation antigen; BCR, B-cell receptor; BH, Bcl-2 homology domain; BiTE, Bispecific T-cell Engager; C5, complement component 5; CD, cluster of differentiation; CIT, chemotherapy-induced thrombocytopenia; CLDN18.2, Claudin-18 isoform 2; DARPin, designed ankyrin repeat proteins; DLBCL, diffuse large B-cell lymphoma; DLL3, delta-like protein 3; EGFR, epidermal growth factor receptor; EGFRvIII, epidermal growth factor receptor variant III; Fab, fragment antigen-binding; FAP, fibroblast activation protein; Fc, fragment crystallizable; FLT3, fms-like tyrosine kinase 3; GEJ, gastroesophageal junction; GM-CSF, granulocyte-macrophage colony-stimulating factor; GvHD, graft versus host disease; HCC, hepatocellular carcinoma; HLE, half-life extended; IL-2R, interleukin 2 receptor; IL-21R, interleukin 21 receptor; IL-2Rα, interleukin 2 receptor alpha; KRAS, Kirsten rat sarcoma; MAC, membrane attack complex; MCL-1, myeloid cell leukemia-1; mCRPC, metastatic castration-resistant prostate cancer; MetMel, metastatic melanoma; MM, multiple myeloma; MOA, mechanism of action; MUC17, mucin 17; NHL, non-Hodgkin's lymphoma; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; PD-L2, programmed cell death ligand 2; PNH, paroxysmal nocturnal hemoglobinuria; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen; RAS, rat sarcoma; R/R, relapsed or refractory; SCLC, small cell lung cancer; STEAP1, six-transmembrane epithelial antigen of prostate 1; TPO, thrombopoietin; TPO-R, thrombopoietin receptor; Treg, regulatory T cell.

Amgen Oncology
Pipeline

Select a button below to learn more

SOLID MALIGNANCIES

MALIGNANCIES

TARGETS

HEMATOLOGIC DISEASES

DISEASES

TARGETS

PIPELINE

BITE® PLATFORM

BIOSIMILARS

MODALITIES

XmAb® ANTIBODY*

Amgen is collaborating with Xencor, Inc. to expand on our own pioneering work in target discovery, protein therapeutics, and bispecific and multispecific antibodies with the XmAb® antibody platform.1 XmAb® technology is an investigational immunomodulatory platform consisting of engineered fragment crystallizable (Fc) domains with selective high affinity binding to create half-life extended T-cell engagers, dual-targeting bispecific antibodies, and multispecific antibodies.1 Multispecific antibodies can be designed with 2 variable domains that require simultaneous binding to 2 tumor-antigen-binding domains, and a CD3-binding domain.1

The XmAb® bispecific Fc domain technology is designed to maintain full-length antibody properties in a bispecific antibody, with the goal of enabling favorable in vivo half-life and simplified manufacturing. These bispecific antibodies are designed to activate T cells at the site of the tumor to fight malignant cells.1

*XmAb® is a registered trademark of Xencor, Inc.

While AMG 509 targets STEAP1 and CD3, not all XmAb® bispecific antibodies include CD3 as a target.

CD, cluster of differentiation; mCRPC, metastatic castration-resistant prostate cancer; STEAP1, six-transmembrane epithelial antigen of prostate 1.

References
1. Moore GL, et al. Methods. 2019;154:38-50. 2. Amgen Pipeline. https://www.amgenpipeline.com. Accessed 9/10/20. 3. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04221542. Accessed 9/10/20.
Molecule
Modality2
Target3
Areas of Investigation3
AMG 509*
Modality2
XmAb® ANTIBODY*
Target3
Areas of Investigation3

*XmAb® is a registered trademark of Xencor, Inc.

While AMG 509 targets STEAP1 and CD3, not all XmAb® bispecific antibodies include CD3 as a target.

CD, cluster of differentiation; mCRPC, metastatic castration-resistant prostate cancer; STEAP1, six-transmembrane epithelial antigen of prostate 1.

References
1. Moore GL, et al. Methods. 2019;154:38-50. 2. Amgen Pipeline. https://www.amgenpipeline.com. Accessed 9/10/20. 3. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04221542. Accessed 9/10/20.

This website may not be accessible on your mobile device; if so, please view on your desktop or tablet.